TY - JOUR
T1 - Postoperative adjuvant Chemotherapy with fluorouracil, doxorubicin, cyclophosphamide, and BCG vaccine. A follow-up report
AU - Buzdar, A. U.
AU - Blumenschein, G. R.
AU - Gutterman, J. U.
AU - Tashima, C. K.
AU - Hortobagyi, G. N.
AU - Smith, T. L.
AU - Campos, L. T.
AU - Wheeler, W. L.
AU - Hersh, Evan M
AU - Freireich, E. J.
AU - Gehan, E. A.
PY - 1979
Y1 - 1979
N2 - 222 patients with stage II or III breast cancer following regional therapy were treated with a combination of fluorouracil, doxorubicin hydrochloride (Adriamycin), cyclophosphamide, and BCG vaccine. At 54 months of study (median follow-up, 30 months), the estimated proportions remaining disease-free two and three years after surgery were 83% and 78%, respectively, in the chemotherapy group and 64% and 55%, respectively, in 151 historical control patients. Estimated two- and three-year survival rates were 93% and 89%, respectively, in the chemotherapy group and 84% and 58%, respectively, in the control patients. Congestive heart failure has developed in three patients, possibly related to the use of doxorubicin. Adjuvant chemotherapy with these drugs was effective in prolonging the disease-free interval and survival of patients irrespective of menopausal status, degree of nodal involvement, or stage of the disease.
AB - 222 patients with stage II or III breast cancer following regional therapy were treated with a combination of fluorouracil, doxorubicin hydrochloride (Adriamycin), cyclophosphamide, and BCG vaccine. At 54 months of study (median follow-up, 30 months), the estimated proportions remaining disease-free two and three years after surgery were 83% and 78%, respectively, in the chemotherapy group and 64% and 55%, respectively, in 151 historical control patients. Estimated two- and three-year survival rates were 93% and 89%, respectively, in the chemotherapy group and 84% and 58%, respectively, in the control patients. Congestive heart failure has developed in three patients, possibly related to the use of doxorubicin. Adjuvant chemotherapy with these drugs was effective in prolonging the disease-free interval and survival of patients irrespective of menopausal status, degree of nodal involvement, or stage of the disease.
UR - http://www.scopus.com/inward/record.url?scp=0018675124&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0018675124&partnerID=8YFLogxK
U2 - 10.1001/jama.242.14.1509
DO - 10.1001/jama.242.14.1509
M3 - Article
C2 - 470088
VL - 242
SP - 1509
EP - 1513
JO - JAMA - Journal of the American Medical Association
JF - JAMA - Journal of the American Medical Association
SN - 0002-9955
IS - 14
ER -